JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1994; 24:1391-1397
© 1994 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoshida, S
Right arrow Articles by Tada, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoshida, S
Right arrow Articles by Tada, M

gamma-Glutamylcysteine ethyl ester for myocardial protection in dogs during ischemia and reperfusion

S Hoshida, T Kuzuya, N Yamashita, M Nishida, S Kitahara, M Hori, T Kamada, and M Tada

First Department of Medicine, Osaka University School of Medicine, Suita, Japan.

OBJECTIVES. The aim of this study was to examine the infarct-limiting effects of gamma-glutamylcysteine ethyl ester, a newly discovered synthetic precursor of glutathione biosynthesis, in a canine model of myocardial infarction. BACKGROUND. Reduced glutathione plays an important role in protecting cells against damage induced by reactive oxygen species during myocardial ischemia and reperfusion. Gamma-glutamylcysteine ethyl ester is capable of penetrating into cells in its intact form and increasing intracellular glutathione levels. METHODS. Dogs were subjected to a 90-min coronary occlusion followed by 5 h of reperfusion. An intravenous bolus injection of gamma-glutamylcysteine ethyl ester (3 or 10 mg/kg body weight) was administered immediately before reperfusion. Regional myocardial blood flow was measured with the use of colored microspheres. RESULTS. Gamma-glutamylcysteine ethyl ester effectively reduced infarct size in a dose-dependent manner (mean +/- SEM 26.4 +/- 3.5% in the low dose group [3 mg/kg, n = 10] and 19.0 +/- 3.4% in the high dose group [10 mg/kg, n = 10]; each p < 0.05 vs. the value in the control group [40.6 +/- 4.8%, n = 10]). There were no differences between the control and treated groups in hemodynamic variables or regional myocardial blood flow either during the ischemic period or after reperfusion. The reduced glutathione content of ischemic myocardium in the control group (0.62 +/- 0.11 mumol/g, p < 0.01) was significantly lower than that in nonischemic myocardium (1.46 +/- 0.07 mumol/g), and it was preserved by treatment in a dose-dependent manner (3 mg/kg, 0.83 +/- 0.06 mumol/g; 10 mg/kg, 0.92 +/- 0.14 mumol/g; each p < 0.05 vs. control level). There were no differences in oxidized glutathione content between nonischemic and ischemic myocardium or among the three groups. CONCLUSIONS. Gamma-glutamylcysteine ethyl ester, a precursor of glutathione, significantly attenuates myocardial ischemia and reperfusion injury when administered immediately before reperfusion.


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Hoshida, N. Yamashita, K. Otsu, T. Kuzuya, and M. Hori
Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats
Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H256 - H262.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S. Kubota, S. Shetty, H. Zhang, S. Kitahara, and R. J. Pomerantz
Novel Inhibitory Effects of gamma -Glutamylcysteine Ethyl Ester against Human Immunodeficiency Virus Type 1 Production and Propagation
Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1200 - 1206.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Hoshida, N. Yamashita, J. Igarashi, K. Aoki, T. Kuzuya, and M. Hori
Long-term Probucol Treatment Reverses the Severity of Myocardial Injury in Watanabe Heritable Hyperlipidemic Rabbits
Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2801 - 2807.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Hoshida, K. Aoki, M. Nishida, N. Yamashita, J. Igarashi, M. Hori, T. Kuzuya, and M. Tada

J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1471 - 1475.
[Abstract]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1994 by the American College of Cardiology Foundation.